×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
YMAB – y-mabs therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
YMAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
08:50 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $23.00 price target on the stock.
11/18
06:57 am
ymab
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
Medium
Report
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]
11/15
03:26 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/9
06:17 am
ymab
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
Low
Report
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... [Yahoo! Finance]
11/8
06:35 am
ymab
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Low
Report
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
11/7
07:18 am
ymab
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings [Yahoo! Finance]
11/4
07:42 am
ymab
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan [Yahoo! Finance]
Neutral
Report
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan [Yahoo! Finance]
11/4
07:35 am
ymab
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
Neutral
Report
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
Date
Time
Symbol
Company Name
Action
%Chg
11/8/2024
06:35 am
YMAB
y-mabs therapeutics, inc.
MISS
Report
-4.7%
y-mabs therapeutics, inc.
8/12/2024
06:30 am
YMAB
y-mabs therapeutics, inc.
MISS
Report
-23.5%
y-mabs therapeutics, inc.
5/7/2024
04:05 pm
YMAB
y-mabs therapeutics, inc.
MISS
Report
-20.9%
y-mabs therapeutics, inc.
2/29/2024
04:05 pm
YMAB
y-mabs therapeutics, inc.
BEAT
Report
11.9%
y-mabs therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:33 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: Paradigm Biocapital Advisors LP
11/12
06:01 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
11/8
07:19 am
ymab
Form 10-Q Y-mAbs Therapeutics, For: Sep 30
Low
Report
Form 10-Q Y-mAbs Therapeutics, For: Sep 30
11/8
06:56 am
ymab
Form 8-K Y-mAbs Therapeutics, For: Nov 08
Low
Report
Form 8-K Y-mAbs Therapeutics, For: Nov 08
11/4
02:16 pm
ymab
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Y-mAbs Therapeutics, Filed by: VANGUARD GROUP INC
11/4
08:51 am
ymab
Form 8-K Y-mAbs Therapeutics, For: Oct 29
Low
Report
Form 8-K Y-mAbs Therapeutics, For: Oct 29
9/20
04:16 pm
ymab
Form 8-K Y-mAbs Therapeutics, For: Sep 17
Medium
Report
Form 8-K Y-mAbs Therapeutics, For: Sep 17
9/20
04:15 pm
ymab
Form 4 Y-mAbs Therapeutics, For: Sep 19 Filed by: Gad Thomas
Medium
Report
Form 4 Y-mAbs Therapeutics, For: Sep 19 Filed by: Gad Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 4 Y-mAbs Therapeutics, For: Mar 17 Filed by: Moller-San Pedro Claus Juan
22.2%
3/18 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.2%
3/13 YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 9.7%
3/24 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 9.3%
1/15 Form 4 Y-mAbs Therapeutics, For: Jan 13 Filed by: Gad Thomas 9.1%
10/31 Form 8-K Y-mAbs Therapeutics, For: Oct 29 7.9%
4/21 Form 8-K Y-mAbs Therapeutics, For: Apr 15 5.8%
5/14 Form 4 Y-mAbs Therapeutics, For: May 13 Filed by: Gad Thomas 5.7%
6/8 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.2%
1/22 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 5.2%
3/18 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.2%
3/13 YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 9.7%
3/24 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 9.3%
1/15 Form 4 Y-mAbs Therapeutics, For: Jan 13 Filed by: Gad Thomas 9.1%
10/31 Form 8-K Y-mAbs Therapeutics, For: Oct 29 7.9%
4/21 Form 8-K Y-mAbs Therapeutics, For: Apr 15 5.8%
5/14 Form 4 Y-mAbs Therapeutics, For: May 13 Filed by: Gad Thomas 5.7%
6/8 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.2%
1/22 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 5.2%
TOP News Decliners
7/1
Form 8-K Y-mAbs Therapeutics, For: Jul 01
-21.3%
3/14 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -16.7%
10/29 Y-mAbs Announces Proposed Public Offering of Common Stock -10.1%
5/10 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus N/A ActVsEst N/A - N/A -10.0%
3/5 Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 -8.7%
6/15 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -6.9%
8/3 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -6.1%
2/27 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
11/1 Form 8-K Y-mAbs Therapeutics, For: Oct 31 -5.6%
10/12 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -5.1%
3/14 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -16.7%
10/29 Y-mAbs Announces Proposed Public Offering of Common Stock -10.1%
5/10 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus N/A ActVsEst N/A - N/A -10.0%
3/5 Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 -8.7%
6/15 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -6.9%
8/3 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -6.1%
2/27 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
11/1 Form 8-K Y-mAbs Therapeutics, For: Oct 31 -5.6%
10/12 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: